Payment overview · 2025
General Payments
$496.42
23 reported records · 11 companies
Healthcare provider profile · identity verified
Katherine D. Carias, M.D.
Allopathic & Osteopathic Physicians|Allergy & Immunology · ASHLAND, KY · NPI 1205828282
Verified facts
What the public records show
CMS Open Payments records show Katherine D. Carias, M.D. received $496.42 in general payments during 2025 across 23 reported records.
GENZYME CORPORATION accounted for 48.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulicity by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAGARD LIQUID as an associated drug or biological on 29 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Gammagard Liquid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $242.40 | 48.8% | 11 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $53.94 | 10.9% | 2 | 2025 |
| Pharming Healthcare, Inc. | Unresolved — no canonical attribution shown | $50.44 | 10.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $31.80 | 6.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.65 | 4.6% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $19.89 | 4.0% | 1 | 2025 |
| BioCryst US Sales Co., LLC | Unresolved — no canonical attribution shown | $19.25 | 3.9% | 1 | 2025 |
| Blueprint Medicines Corporation | Unresolved — no canonical attribution shown | $18.02 | 3.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.56 | 2.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.56 | 2.7% | 1 | 2025 |
| ADMA BioManufacturing LLC | Unresolved — no canonical attribution shown | $10.91 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $485.51 | 22 |
| Consulting Fee | $10.91 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $242.40 | 11 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $53.94 | 2 | 2025 |
Source payment records
|
|||||
| RUCONEST Normalized: ruconest |
Biological | Pharming Healthcare, Inc. | $50.44 | 1 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $27.12 | 2 | 2025 |
Source payment records
|
|||||
| EBGLYSS Normalized: ebglyss |
Drug | Lilly USA, LLC | $22.65 | 1 | 2025 |
Source payment records
|
|||||
| CUVITRU Normalized: cuvitru |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $19.89 | 1 | 2025 |
Source payment records
|
|||||
| ORLADEYO Normalized: orladeyo |
Drug | BioCryst US Sales Co., LLC | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| AYVAKIT Normalized: ayvakit |
Drug | Blueprint Medicines Corporation | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 118 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
30 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
36 | 36 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
118 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
111 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAGARD LIQUID open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 8 recipient NPIs · example record 1223786557 |
Gammagard Liquid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 806 | 160 |
| Eliquis | Apixaban | 754 | 88 |
| Levothyroxine Sodium | Levothyroxine Sodium | 733 | 142 |
| Potassium Chloride | Potassium Chloride | 672 | 124 |
| Furosemide | Furosemide | 664 | 143 |
| Pantoprazole Sodium | Pantoprazole Sodium | 533 | 107 |
| Metoprolol Tartrate | Metoprolol Tartrate | 473 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 457 | 84 |
| Sertraline Hcl | Sertraline Hcl | 371 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 363 | 67 |
| Famotidine | Famotidine | 360 | 71 |
| Omeprazole | Omeprazole | 340 | 72 |
| Montelukast Sodium | Montelukast Sodium | 334 | 78 |
| Lisinopril | Lisinopril | 329 | 68 |
| Buspirone Hcl | Buspirone Hcl | 320 | 69 |
| Carvedilol | Carvedilol | 310 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 305 | 67 |
| Mirtazapine | Mirtazapine | 277 | 48 |
| Trazodone Hcl | Trazodone Hcl | 272 | 60 |
| Clopidogrel | Clopidogrel Bisulfate | 271 | 56 |
| Fluticasone Propionate | Fluticasone Propionate | 266 | 92 |
| Ondansetron Hcl | Ondansetron Hcl | 205 | 84 |
| Duloxetine Hcl | Duloxetine Hcl | 187 | 32 |
| Xarelto | Rivaroxaban | 173 | 15 |
| Divalproex Sodium | Divalproex Sodium | 172 | 29 |
| Allopurinol | Allopurinol | 169 | 25 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 169 | 74 |
| Lactulose | Lactulose | 169 | 39 |
| Losartan Potassium | Losartan Potassium | 164 | 26 |
| Prednisone | Prednisone | 155 | 71 |
| Sucralfate | Sucralfate | 150 | 20 |
| Donepezil Hcl | Donepezil Hcl | 147 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 138 | 23 |
| Levetiracetam | Levetiracetam | 133 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 127 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 124 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 120 | 74 |
| Escitalopram Oxalate | Escitalopram Oxalate | 120 | 22 |
| Doxycycline Hyclate | Doxycycline Hyclate | 119 | 59 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 118 | 28 |
| Simvastatin | Simvastatin | 115 | 19 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 113 | 31 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 112 | 23 |
| Jardiance | Empagliflozin | 111 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 108 | 37 |
| Quetiapine Fumarate | Quetiapine Fumarate | 108 | 26 |
| Azelastine Hcl | Azelastine Hcl | 107 | 36 |
| Gemfibrozil | Gemfibrozil | 106 | 13 |
| Spironolactone | Spironolactone | 106 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 105 | 26 |
| Gabapentin | Gabapentin | 103 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 103 | 19 |
| Metformin Hcl | Metformin Hcl | 103 | 21 |
| Memantine Hcl | Memantine Hcl | 102 | 19 |
| Nystatin | Nystatin | 100 | 53 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 94 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 90 | 15 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 87 | 31 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 81 | 13 |
| Risperidone | Risperidone | 80 | 12 |
| Primidone | Primidone | 79 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 76 | 14 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 75 | 19 |
| Myrbetriq | Mirabegron | 75 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 74 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 72 | 41 |
| Midodrine Hcl | Midodrine Hcl | 70 | 29 |
| Azithromycin | Azithromycin | 69 | 42 |
| Tramadol Hcl | Tramadol Hcl | 69 | 22 |
| Diltiazem Hcl | Diltiazem Hcl | 65 | suppressed |
| Finasteride | Finasteride | 65 | 15 |
| Latanoprost | Latanoprost | 64 | 14 |
| Alendronate Sodium | Alendronate Sodium | 63 | 16 |
| Cephalexin | Cephalexin | 63 | 26 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 62 | 13 |
| Insulin Aspart Flexpen | Insulin Aspart | 62 | 27 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 61 | 13 |
| Digoxin | Digoxin | 61 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 60 | 20 |
| Linzess | Linaclotide | 60 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | suppressed |
| Klor-Con 10 | Potassium Chloride | 58 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 57 | 38 |
| Glipizide | Glipizide | 56 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 56 | 35 |
| Baclofen | Baclofen | 54 | 11 |
| Januvia | Sitagliptin Phosphate | 54 | suppressed |
| Cefdinir | Cefdinir | 53 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 14 |
| Meloxicam | Meloxicam | 53 | suppressed |
| Glimepiride | Glimepiride | 50 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 50 | 25 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 50 | 21 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 49 | 18 |
| Constulose | Lactulose | 48 | 30 |
| Ozempic | Semaglutide | 48 | 13 |
| Anastrozole | Anastrozole | 47 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 46 | suppressed |
| Ibuprofen | Ibuprofen | 45 | 16 |
| Clonidine Hcl | Clonidine Hcl | 44 | 18 |
| Humalog Kwikpen U-100 | Insulin Lispro | 44 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 43 | 28 |
| Cilostazol | Cilostazol | 42 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 42 | 21 |
| Meclizine Hcl | Meclizine Hcl | 42 | 19 |
| Bupropion Hcl Sr | Bupropion Hcl | 41 | suppressed |
| Fluconazole | Fluconazole | 41 | 28 |
| Lorazepam | Lorazepam | 41 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 41 | suppressed |
| Torsemide | Torsemide | 41 | 18 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 40 | 19 |
| Nifedipine Er | Nifedipine | 40 | 11 |
| Aripiprazole | Aripiprazole | 39 | suppressed |
| Bupropion Xl | Bupropion Hcl | 39 | suppressed |
| Entresto | Sacubitril/Valsartan | 39 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 39 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 39 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 38 | 15 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 36 | 36 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 16 |
| Ketoconazole | Ketoconazole | 36 | 15 |
| Spiriva Respimat | Tiotropium Bromide | 36 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 35 | suppressed |
| Levofloxacin | Levofloxacin | 35 | 21 |
| Novolog Flexpen | Insulin Aspart | 35 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 35 | 15 |
| Epinephrine | Epinephrine | 34 | 23 |
| Lidocaine Hcl | Lidocaine Hcl | 34 | 26 |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 33 | 18 |
| Brilinta | Ticagrelor | 33 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 33 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 33 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | suppressed |
| Fentanyl | Fentanyl | 32 | suppressed |
| Lamotrigine | Lamotrigine | 32 | suppressed |
| Levemir Flexpen | Insulin Detemir | 32 | suppressed |
| Roflumilast | Roflumilast | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Celecoxib | Celecoxib | 30 | suppressed |
| Ranolazine Er | Ranolazine | 30 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 30 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 29 | 11 |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Mupirocin | Mupirocin | 29 | 22 |
| Sps | Sodium Polystyrene Sulfon/Sorb | 29 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 28 | 13 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 27 | 16 |
| Bumetanide | Bumetanide | 27 | suppressed |
| Dupixent Pen | Dupilumab | 27 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 26 | 15 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 26 | suppressed |
| Methylprednisolone Sodium Succ | Methylprednisolone Sod Succ | 26 | 19 |
| Lubiprostone | Lubiprostone | 25 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 25 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Metolazone | Metolazone | 25 | suppressed |
| Olanzapine | Olanzapine | 25 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 25 | suppressed |
| Cimetidine | Cimetidine | 24 | suppressed |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Haloperidol | Haloperidol | 23 | 12 |
| Scopolamine | Scopolamine | 23 | suppressed |
| Acetic Acid | Acetic Acid | 22 | suppressed |
| Humalog | Insulin Lispro | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Dapsone | Dapsone | 21 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | 16 |
| Topiramate | Topiramate | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 20 | suppressed |
| Clonidine | Clonidine | 20 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 20 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Dofetilide | Dofetilide | 19 | suppressed |
| Meropenem | Meropenem | 19 | suppressed |
| Xifaxan | Rifaximin | 19 | suppressed |
| Alprazolam | Alprazolam | 18 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 18 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 15 |
| Santyl | Collagenase Clostridium Hist. | 18 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 18 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 11 |
| Dexamethasone | Dexamethasone | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Dulera | Mometasone/Formoterol | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Rytary | Carbidopa/Levodopa | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 15 | 12 |
| Nadolol | Nadolol | 15 | suppressed |
| Rivastigmine | Rivastigmine | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 13 | suppressed |
| Meropenem-0.9% Nacl | Meropenem-0.9% Sodium Chloride | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 13 | 12 |
| Tamoxifen Citrate | Tamoxifen Citrate | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Zonisamide | Zonisamide | 13 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Asceniv | Immune Globulin,gamma(Igg)slra | 11 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Fluticasone-Salmeterol Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Insulin Aspart Prot Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Mirabegron Er | Mirabegron | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Procrit | Epoetin Alfa | 11 | suppressed |
| Ramelteon | Ramelteon | 11 | suppressed |
| Sodium Chloride | Sodium Chloride 0.45 % | 11 | suppressed |
| Uzedy | Risperidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $496.42 · 23 records | GENZYME CORPORATION | AYVAKIT, CUVITRU, DUPIXENT, EBGLYSS, NUCALA, ORLADEYO, Prolastin-C Liquid, RUCONEST, TEZSPIRE, TRELEGY ELLIPTA | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error